Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma

Hyun Jik Kim, Chang-Hoon Kim, Bong Jae Lee, Yoo Sam Chung, Jin Kook Kim, Yoon Seok Choi, Joo Heon Yoon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy. Methods: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years. Results: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68%. The survival rate for patients (n = 6) who received concurrent chemoradiotherapy was 42%. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression. Conclusion: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.

Original languageEnglish
Pages (from-to)493-498
Number of pages6
JournalAuris Nasus Larynx
Volume34
Issue number4
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Olfactory Esthesioneuroblastoma
Chemoradiotherapy
Survival Rate
Therapeutics
Radiotherapy
Recurrence
Salvage Therapy
Neoplasms
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Otorhinolaryngology

Cite this

Kim, Hyun Jik ; Kim, Chang-Hoon ; Lee, Bong Jae ; Chung, Yoo Sam ; Kim, Jin Kook ; Choi, Yoon Seok ; Yoon, Joo Heon. / Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma. In: Auris Nasus Larynx. 2007 ; Vol. 34, No. 4. pp. 493-498.
@article{72cb7703952a4dbdb86c16b5d80e31ac,
title = "Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma",
abstract = "Objective: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy. Methods: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years. Results: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68{\%}. The survival rate for patients (n = 6) who received concurrent chemoradiotherapy was 42{\%}. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression. Conclusion: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.",
author = "Kim, {Hyun Jik} and Chang-Hoon Kim and Lee, {Bong Jae} and Chung, {Yoo Sam} and Kim, {Jin Kook} and Choi, {Yoon Seok} and Yoon, {Joo Heon}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.anl.2007.02.005",
language = "English",
volume = "34",
pages = "493--498",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma. / Kim, Hyun Jik; Kim, Chang-Hoon; Lee, Bong Jae; Chung, Yoo Sam; Kim, Jin Kook; Choi, Yoon Seok; Yoon, Joo Heon.

In: Auris Nasus Larynx, Vol. 34, No. 4, 01.12.2007, p. 493-498.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma

AU - Kim, Hyun Jik

AU - Kim, Chang-Hoon

AU - Lee, Bong Jae

AU - Chung, Yoo Sam

AU - Kim, Jin Kook

AU - Choi, Yoon Seok

AU - Yoon, Joo Heon

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Objective: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy. Methods: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years. Results: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68%. The survival rate for patients (n = 6) who received concurrent chemoradiotherapy was 42%. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression. Conclusion: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.

AB - Objective: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis. Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear. We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy. Methods: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years. Results: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68%. The survival rate for patients (n = 6) who received concurrent chemoradiotherapy was 42%. The difference in the survival rate was not statistically significant, and no difference in the recurrence rate between the two groups. In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate. In the group having concurrent chemoradiotherapy, no patient experienced primary tumor progression. Conclusion: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma. However, concurrent chemoradiotherapy may be another primary treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=35349030723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349030723&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2007.02.005

DO - 10.1016/j.anl.2007.02.005

M3 - Article

VL - 34

SP - 493

EP - 498

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 4

ER -